Reference
Leist T, et al. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Multiple Sclerosis and Related Disorders 46: 1-8, Nov 2020. Available from: URL: http://doi.org/10.1016/j.msard.2020.102572
Rights and permissions
About this article
Cite this article
Cladribine. Reactions Weekly 1841, 79 (2021). https://doi.org/10.1007/s40278-021-90581-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-90581-7